A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
Public ClinicalTrials.gov record NCT00367887. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).
Study identification
- NCT ID
- NCT00367887
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2006 (Type not available)
- Primary completion
- Jul 2008 (Actual)
- Completion
- Jul 2008 (Actual)
- Last update posted
- Feb 11, 2013
2006 – 2008
United States locations
- U.S. sites
- 34
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anaheim | California | 92801 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92067 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Pasadena | California | 91105 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | San Diego | California | 92161 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | San Francisco | California | 94121 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32610 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30309 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01655 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Plymouth | Minnesota | 55446 | — |
| Pfizer Investigational Site | Saint Paul | Minnesota | 55117 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63104 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87131 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | The Bronx | New York | 10461 | — |
| Pfizer Investigational Site | The Bronx | New York | 10468 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27599-7209 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19141 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Annandale | Virginia | 22003 | — |
| Pfizer Investigational Site | Fairfax | Virginia | 22031 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00367887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00367887 live on ClinicalTrials.gov.